USPTO serial 79446284
Serial No. 79446284
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GULIANO, ROBERT N
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with Serial No. 79446284?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Zaccaria
John Zaccaria Notaro, Michalos & Zaccaria P.C.100 Dutch Hill Road, Suite 240Orangeburg, NY 10962United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietetic foods adapted for medical purposes; teeth filling material; herbicides; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of rare diseases, namely, for Sarcomas and Systemic Mastocytosis; pharmaceutical preparations for the treatment of neuroendocrine disorders; fungicides; food for babies; dietetic substances in the nature of dietetic foods adapted for medical use; disinfectants; nutritional supplements for medical purposes; homogenized food adapted for medical purposes; analgesics; anaesthetics; antibiotics; anti-inflammatories; Food supplements, namely, anti-oxidants in pill form; dietetic beverages adapted for medical purposes; vitamin supplement patches; dietary fibre supplements; glycerine for medical purposes; immunostimulants; protein dietary supplements; mineral dietary supplements; dietary supplements for human beings; medicated lotions for pharmaceutical purposes; narcotics being pharmaceuticals for the treatment of pain; opiates being pharmaceuticals for the treatment of pain; Pharmaceutical preparations in the form of pastilles for the treatment of cancer; Pharmaceutical preparations in the form of pastilles for the treatment of pain; Pharmaceutical preparations in the form of pastilles for the treatment of rare diseases, namely, for Sarcomas and Systemic Mastocytosis; Pharmaceutical preparations in the form of pastilles for the treatment of neuroendocrine disorders; chemical preparations for pharmaceutical purposes for the treatment of cancer; chemical preparations for pharmaceutical purposes for the treatment of pain; chemical preparations for pharmaceutical purposes for the treatment of rare diseases, namely, for Sarcomas and Systemic Mastocytosis; chemical preparations for pharmaceutical purposes for the treatment of neuroendocrine disorders; chemical preparations for medical purposes for the treatment of cancer; chemical preparations for medical purposes for the treatment of pain; chemical preparations for medical purposes for the treatment of rare diseases, namely, for Sarcomas and Systemic Mastocytosis; chemical preparations for medical purposes for the treatment of pain; chemical preparations for medical purposes for the treatment of neuroendocrine disorders; Aloe vera preparations for pharmaceutical purposes; phytotherapy preparations for medical purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer-related conditions; vitamin preparations; chemico-pharmaceutical preparations for the treatment of cancer; chemico-pharmaceutical preparations for the treatment of pain; chemico-pharmaceutical preparations for the treatment of rare diseases, namely, for Sarcomas and Systemic Mastocytosis; chemico-pharmaceutical preparations for the treatment of neuroendocrine disorders | ACTIVE | — |
| 035 | Retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; marketing services; advertising services | ACTIVE | — |
| 041 | Arranging and conducting of in-person educational forums in the field of pharmaceuticals; Educational services in the nature of pharmaceuticals schools; providing information in the field of education; providing online electronic publications, not downloadable, namely, brochures in the field of pharmaceuticals; arranging and conducting of conferences in the field of pharmaceuticals; arranging and conducting of congresses in the field of pharmaceuticals; arranging and conducting of colloquiums in the field of pharmaceuticals; arranging and conducting of seminars in the field of pharmaceuticals; arranging and conducting of symposiums in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 8, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 2, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 12, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 4, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 4, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 4, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 4, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 8, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 23, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 21, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 21, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 2, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 1, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 20, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 19, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |